ZURICH (Reuters) – Swiss drugmaker Roche said on Friday its experimental medicine ipatasertib hit one goal of a late-stage clinical trial against a small slice of patients with a kind of prostate cancer but fell short in the overall study population.
The drug, mixed with other medicines, hit its target of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumours had PTEN loss.
In the broader study group, however, the target of rPFS was not met, Roche said in a statement, adding the trial will continue to the next analysis.
(Reporting by John Miller; editing by Thomas Seythal)
